Nationwide Trends in Incidence, Healthcare Utilization, and Mortality in Hospitalized Acute Myocardial Infarction Patients in Taiwan
Study Details
Study Description
Brief Summary
This was a retrospective study using the Taiwan's National Health Insurance Research Database (NHIRD). The study employed two study designs for different purposes as follows:
-
A cross-sectional analysis was conducted to explore the annual incidence trends.
-
A longitudinal cohort study was conducted to assess baseline characteristics, treatment patterns, long-term healthcare utilization, and cause-specific mortality among incident AMI patients.
In each part, the study was conducted for AMI, and separately for ST-segment elevation and non-ST- segment elevation myocardial infarction (STEMI and NSTEMI)
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| AMI Patients with AMI |
|
| STEMI Patients with STEMI |
|
| NSTEMI Patients with NSTEMI |
Outcome Measures
Primary Outcome Measures
- Mean age of patients [12 months]
- Number of male patients [12 months]
- Year of patient entry into cohort [12 months]
- Number of patients with AMI in Taiwan [12 months]
- Number of patients with STEMI in Taiwan [12 months]
- Number of patients with NSTEMI in Taiwan [12 months]
- Number of AMI patients with comorbidities [Up to 3 years]
- Number of patients with treatment for AMI [Up to 3 years]
- Number of STEMI patients with comorbidities [Up to 3 years]
- Number of patients with treatment for STEMI [Up to 3 years]
- Number of NSTEMI patients with comorbidities [Up to 3 years]
- Number of patients with treatment for NSTEMI [Up to 3 years]
- Number of mortalities among AMI patients [Up to 3 years]
- Number of mortalities among STEMI patients [Up to 3 years]
- Number of mortalities among NSTEMI patients [Up to 3 years]
- Number of AMI patients with outpatient visits [Up to 3 years]
- Number of AMI patients with emergency room visits [Up to 3 years]
- Number of AMI patients with hospitalizations [Up to 3 years]
- Length of hospital stay for AMI patients [Up to 3 years]
- Direct medical costs for AMI patients [Up to 3 years]
- Number of STEMI patients with outpatient visits [Up to 3 years]
- Number of STEMI patients with emergency room visits [Up to 3 years]
- Number of STEMI patients with hospitalizations [Up to 3 years]
- Length of hospital stay for STEMI patients [Up to 3 years]
- Direct medical costs for STEMI patients [Up to 3 years]
- Number of NSTEMI patients with outpatient visits [Up to 3 years]
- Number of NSTEMI patients with emergency room visits [Up to 3 years]
- Number of NSTEMI patients with hospitalizations [Up to 3 years]
- Length of hospital stay for NSTEMI patients [Up to 3 years]
- Direct medical costs for NSTEMI patients [Up to 3 years]
Eligibility Criteria
Criteria
Inclusion Criteria:
Cross-sectional analysis:
-
Patients aged 20 years and older.
-
Patients who had been admitted for AMI, defined as primary or first secondary diagnosis of AMI between 2014 and 2020.
-
The diagnosis of AMI/ STEMI/ NSTEMI was identified by the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes and 10th revision (ICD-10-CM) codes.
-
Incident cases of AMI hospitalization were defined as no history of AMI-related hospitalization or outpatient visit within 1 year before admission.
Longitudinal analysis:
Patients aged 20 years and older.
-
Patients who had been admitted for AMI, defined as primary or first secondary diagnosis of AMI between 2014 and 2017.
-
The diagnosis of AMI/ STEMI/ NSTEMI was identified by ICD-9-CM codes and ICD-10-CM codes. (The ICD-9-CM code and ICD-10-CM codes were the same as above)
-
Incident cases of AMI hospitalization were defined as no history of AMI-related hospitalization or outpatient visit within 1 year before admission.
-
The cohort entry date was defined as the admission date of incident AMI hospitalization, and the index date was defined as the discharge date of incident hospitalization.
Exclusion Criteria:
None specified
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Novartis | Taipei | Taiwan |
Sponsors and Collaborators
- Novartis Pharmaceuticals
Investigators
- Study Director: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CLCZ696BTW05